An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
- 7 May 2013
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 40 (9) , 1312-1320
Abstract
The role of interim PET/CT in guiding therapeutic strategies in diffuse large B-cell lymphoma (DLBCL) is debated, mainly because interpretation rules vary among centres. This study aimed to explore the reproducibility and confirm the prognostic value of early PET/CT using the Deauville criteria and ΔSUVmax. This international confirmatory study retrospectively evaluated 114 patients with newly diagnosed DLBCL treated with a rituximab-containing regimen. All patients underwent 18F-FDG PET/CT at baseline (PET0) and after two cycles (PET2), with no therapy change based on the latter. Scans were interpreted by three observers using the Deauville five-point scale and ΔSUVmax between PET0 and PET2 was calculated. Interpretations were evaluated for interobserver agreement and for progression-free survival (PFS) prediction. Median follow-up was 39 months. Early PET/CT was predictive of outcome when interpreted with the Deauville criteria and ΔSUVmax. Using the five-point scale, the overall kappa value was 0.66 with the reference background set in the liver (score ≥4) and interobserver agreement was even better using a 66 % ΔSUVmax cut-off (κ = 0.83). Moreover, the prognostic value of interim PET was slightly inferior when using a Deauville score ≥4 than when using a 66 % ΔSUVmax cut-off: for the Deauville score the 3-year PFS estimate was 59 % (45–73 %) in PET2-positive patients vs. 81 % (71–91 %) in PET2-negative patients (P = 0.003); for the 66 % ΔSUVmax cut-off the 3-year PFS estimate was 44 % (23–65 %) in PET2-positive patients vs. 79 % (70–88 %) in PET2-negative patients (P = 0.0002). Although the Deauville criteria are valid for assessing the prognostic value of early PET/CT in DLBCL, computation of the ΔSUVmax leads to better performance and interobserver reproducibility, and should be preferred when a baseline scan is available.Keywords
This publication has 25 references indexed in Scilit:
- Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensusLeukemia & Lymphoma, 2012
- Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOPBlood, 2012
- SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphomaBlood, 2011
- Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteriaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Can the Interim Fluorodeoxyglucose–Positron Emission Tomography Standardized Uptake Value Be Used to Determine the Need for Residual Mass Biopsy After Dose-Dense Immunochemotherapy for Advanced Diffuse Large B-Cell Lymphoma?Journal of Clinical Oncology, 2010
- Interim PET in lymphoma: a step towards standardizationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV-A feasibility studyEuropean Radiology, 2008
- Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual AnalysisJournal of Nuclear Medicine, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007